# US 2012/0252774 A1 · Steroid tetrol solid state forms - 2

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252774 A1
- Document ID: US20120252774A1
- Status: Published application
- Kind: A1
- Application number: 13/328,760
- Filed: 2011-12-16
- Published: 2012-10-04
- Earliest claimed: 2010-12-17
- Inventors: Steven K. White; Erin E. Jansen
- Web page: https://patentgrep.com/patent/US20120252774A1

## CPC

- C07J 1/00: Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- A61K 31/568: substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07J 1/0022: {the substituent being an OH group free esterified or etherified}
- C07J: STEROIDS (seco-steroids C07C)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to solid state forms of androst-5-ene-3α,7β,16β,17β-tetrol, formulations containing or prepared from such solid state forms and use of these materials for modulating unwanted inflammation including acute and chronic non-productive inflammation. The formulations can be used to prevent, treat or slow the progression of conditions related to autoimmunity and metabolic disorders such as arthritis, multiple sclerosis, ulcerative colitis, Type 1 diabetes and Type 2 diabetes.

## Claims

### Claim 1

Crystalline androst-5-ene-3α,7β,16α,17β-tetrol.

### Claim 2 (depends on 1)

The crystalline androst-5-ene-3α,7β,16α,17β-tetrol of claim 1 wherein crystalline androst-5-ene-3α,7β,16α,17β-tetrol is a crystalline anhydrate.

### Claim 3 (depends on 1)

The crystalline androst-5-ene-3α,7β,16α,17β-tetrol of claim 1 wherein crystalline androst-5-ene-3α,7β,16α,17β-tetrol is Form Iα or Form IIα 3α-tetrol.

### Claim 4 (depends on 3)

The crystalline androst-5-ene-3α,7β,16α,17β-tetrol of claim 3 wherein crystalline androst-5-ene-3α,7β,16α,17β-tetrol is Form Iα 3α-tetrol characterized by (1) an XRPD pattern having three or more peaks selected from the group consisting of about 7.6, 16.1, 17.8, 19.8 and 22.2 degree 2-theta or (2) DTA thermogram, obtained with a temperature ramp of 10° C./min, having a prominent endotherm centered at about 224° C. and an exotherm centered at about 154° C. or (1) and (2).

### Claim 5 (depends on 4)

The crystalline androst-5-ene-3α,7β,16α,17β-tetrol of claim 4 wherein the XRPD pattern further has one or more peaks selected from the group consisting of about 13.7, 15.3, 16.5, 17.0 and 20.9 degree 2-theta.

### Claim 6 (depends on 4)

The crystalline androst-5-ene-3α,7β,16α,17β-tetrol of claim 4 wherein the 224° C. DTA endotherm has an onset temperature of about 216° C.

### Claim 7 (depends on 4)

The crystalline androst-5-ene-3α,7β,16α,17β-tetrol of claim 4 wherein crystalline androst-5-ene-3α,7β,16α,17β-tetrol is further characterized by TGA thermogram, obtained with a temperature ramp of 10° C./min, having (1) negligible weight loss from about 60° C. to about 140° C. or (2) about 2% wt loss from about 60° C. to about the onset of the prominent endotherm or (1) and (2).

### Claim 8 (depends on 3)

The crystalline androst-5-ene-3α,7β,16α,17β-tetrol of claim 3 wherein crystalline androst-5-ene-3α,7β,16α,17β-tetrol is Form IIα 3α-tetrol characterized by (1) DTA thermogram, obtained with a temperature ramp of 10° C./min, having a prominent endotherm centered at about 243° C.

### Claim 9 (depends on 8)

The crystalline androst-5-ene-3α,7β,16α,17β-tetrol of claim 8 wherein the 243 oC DTA endotherm has (1) an onset temperature of about 229° C. or (2) a shoulder between about 230 to 240° C. or (1) and (2).

### Claim 10

Amorphous androst-5-ene-3α,7β,16α,17β-tetrol.

### Claim 11 (depends on 10)

The amorphous androst-5-ene-3α,7β,16α,17β-tetrol of claim 10 characterized by (1) XRPD pattern having a broad band from about 11 degree 2-theta to about 20 degree 2-theta or a broad band centered between about 16 to 17 degree 2-theta or (2) DTA thermogram, obtained with a temperature ramp of 10° C./min, having a prominent exotherm centered at about 166° C. or (1) and (2).

### Claim 12 (depends on 11)

The amorphous androst-5-ene-3α,7β,16α,17β-tetrol of claim 11 wherein the DTA thermogram further has an endotherm centered at about 225° C.

### Claim 13 (depends on 12)

The amorphous androst-5-ene-3α,7β,16α,17β-tetrol of claim 12 wherein the 225° C. DTA endotherm has a shoulder at about 220° C.

### Claim 14 (depends on 11)

The amorphous androst-5-ene-3α,7β,16α,17β-tetrol of claim 11 further characterized by TGA thermogram with negligible % weight loss between about 60° C. to about 140° C.

### Claim 15

A composition comprising one or more excipients and a solid state form of androst-5-ene-3α,7β,16α,17β-tetrol.

### Claim 16 (depends on 15)

The composition of claim 15 wherein the solid state form is crystalline androst-5-ene-3α,7β,16α,17β-tetrol.

### Claim 17 (depends on 15)

The composition of claim 15 wherein the solid state form is a crystalline anhydrate.

### Claim 18 (depends on 17)

The composition of claim 17 wherein the crystalline anhydrate is Form Iα 3α-tetrol.

### Claim 19 (depends on 17)

The composition of claim 17 wherein the crystalline anhydrate is Form IIα 3α-tetrol.

### Claim 20

A method of preparing a liquid formulation comprising admixing a solid state form of androst-5-ene-3α,7β,16α,17β-tetrol with a liquid excipient.

### Claim 21 (depends on 20)

The method of claim 20 wherein the solid state form is crystalline androst-5-ene-3α,7β,16α,17β-tetrol.

### Claim 22 (depends on 20)

The method of claim 20 the solid state form of androst-5-ene-3α,7β,16α,17β-tetrol is a crystalline anhydrate.

### Claim 23 (depends on 13)

The method of claim 13 wherein the crystalline anhydrate is Form Iα or Form IIα 3α-tetrol.

### Claim 24 (depends on 20)

The method of claim 20 wherein the solid state form is amorphous 3α-tetrol.

### Claim 25

A method of treating unwanted inflammation, comprising administering an effective amount of a solid formulation to a subject in need thereof wherein the solid formulation comprises a solid state form of androst-5-ene-3α,7β,16α,17β-tetrol and one or more excipients.

### Claim 26 (depends on 25)

The method of claim 25 wherein the solid state form is crystalline androst-5-ene-3α,7β,16α,17β-tetrol.

### Claim 27 (depends on 25)

The method of claim 25 wherein the solid state form is a crystalline anhydrate.

### Claim 28 (depends on 27)

The method of claim 27 wherein the crystalline anhydrate is Form Iα or Form IIα 3α-tetrol.

### Claim 29 (depends on 25)

The method of claim 25 wherein the solid state form is amorphous 3α-tetrol.

### Claim 30 (depends on 25)

The method of claim 25 wherein the unwanted inflammation is a condition or disease associated with chronic, non-production inflammation.

### Claim 31 (depends on 30)

The method of claim 30 wherein the condition or disease is an autoimmune condition or disease.

### Claim 32 (depends on 30)

The method of claim 30 wherein the condition or disease is a metabolic condition or disease.

### Claim 33 (depends on 31)

The method of claim 31 wherein the autoimmune disease is Type 1 diabetes.

### Claim 34 (depends on 31)

The method of claim 31 wherein the autoimmune disease is a lupus condition, systemic lupus erythematosus or discoid lupus

### Claim 35 (depends on 30)

The method of claim 30 wherein the condition or disease is an arthritis condition or rheumatoid arthritis.

### Claim 36 (depends on 30)

The method of claim 30 wherein the condition or disease is an inflammatory bowel disease, ulcerative colitis or Crohn's disease (regional enteritis).

### Claim 37 (depends on 30)

The method of claim 30 wherein the condition or disease is a lung inflammation condition, cystic fibrosis, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome, acute asthma, chronic asthma, emphysema, acute bronchitis, allergic bronchitis, chronic bronchitis, a fibrosing alveolitis (lung fibrosis) condition or subepithelial fibrosis in patients having chronic bronchitis, asthma and/or COPD.

### Claim 38 (depends on 30)

The method of claim 30 wherein the condition or disease is a neurodegenerative condition, Parkinson's disease or Alzheimer's disease.

### Claim 39 (depends on 30)

The method of claim 30 wherein the condition or disease is a hyperproliferation condition or cancer.

### Claim 40 (depends on 30)

The method of claim 30 wherein the condition or disease is a liver cirrhosis condition, nonalcoholic steatohepatitis (NASH) or nonalcoholic fatty liver disease.

### Claim 41 (depends on 32)

The method of claim 32 wherein the metabolic condition or disease is type 2 diabetes, obesity, insulin resistance, hyperglycemia, impaired glucose utilization or tolerance, or impaired or reduced insulin synthesis.
